QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

VRDN

QT65Viridian Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
16.63
-0.08-0.48%
OverviewShort InterestFilings
VRDNQT65Viridian Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
16.63-0.48%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-17.07
Insider Own-
Shs Outstand-
Perf Week3.04%
Market Cap1.50BForward P/E-EPS next Y-2.42Insider Trans-Shs Float-Perf Month4.13%
Enterprise Value1.38BPEG-EPS next Q-1.03Inst Own-Short Float-Perf Quarter-40.27%
Income-317464334.00P/S21.21EPS this Y77.91%Inst Trans-Short Ratio-Perf Half Y-49.38%
Sales70.92MP/B2.69EPS next Y35.80%ROA-45.70%Short Interest-Perf YTD-46.56%
Book/sh-P/C-EPS next 5Y-ROE-60.70%52W High34.29 -51.50%Perf Year12.06%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-52.27%52W Low13.18 26.18%Perf 3Y-
Dividend Est.-EV/EBITDA-3.95Sales past 3/5Y228.66% 134.56%Gross Margin99.38%Volatility2.77% 3.34%Perf 5Y-
Dividend TTM-EV/Sales19.44EPS Y/Y TTM16.58%Oper. Margin-543.86%ATR (14)0.86Perf 10Y-
Dividend Ex-Date-Quick Ratio15.15Sales Y/Y TTM-Profit Margin-508.46%RSI (14)50.79Recom2.00
Dividend Gr. 3/5Y-Current Ratio15.15EPS Q/Q-3.45%SMA200.27%Beta1.20Target Price36.86
Payout0.00%Debt/Eq0.08Sales Q/Q-SMA504.73%Rel Volume1.64Prev Close16.71
Employees143LT Debt/Eq0.07EarningsAug 05SMA200-31.17%Avg Volume2.46MPrice16.63
IPO DateJun 18, 2014Option/ShortYes / YesEPS/Sales Surpr.15.09% -Net Debt/EBITDA0.36Volume4,027,378Change-0.48%
Analyst Ratings
DateActionAnalystRatingTarget
May-15-26ReiteratedEvercore ISI$27 → $26
May-13-26ReiteratedStifel Nicolaus$48 → $39
May-06-26ReiteratedRBC CapitalOutperform$45 → $34
Apr-21-26ReiteratedTruist Financial$36 → $33
Apr-08-26ReiteratedTruist Financial$40 → $36
Apr-08-26ReiteratedWedbushOutperform$31
Feb-26-26ReiteratedJefferies$45
Jan-28-26ReiteratedEvercore ISI$44 → $45
Jan-20-26ReiteratedEvercore ISI$42 → $44
Jan-07-26InitiatedUBSBuy$50
Latest News
Jun-10-26
Jun-10-2612:02AM
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue6710
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A2400
Gross Profit-19710
Selling, General and Administrative Excl. Other129561
Research and Development32339238
Other Operating Expense-700
Operating Income-38-363-299
Interest Expense053
Unusual Expense
———
Non-Operating Income (Expense)-2-26-32
Net Income Before Taxes-38-343-270
Income Taxes
000
Consolidated Net Income-38-343-270
Net Income From Continuing Operations-38-343-270
Net Income-38-343-270
EPS (Recurring)-17.07-3.32-3.98
EPS (Basic, Before Extraordinaries)-17.07-3.32-3.98
EPS (Diluted)-17.07-3.32-3.98
EBITDA-36-337-266
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio8.3237.26—
Gross Margin-316.67100.00—
Operating Margin-633.33-511.27—
Net Margin-633.33-483.10—
Shares Outstanding38568
Market Capitalization502,645—
Operating Lease Expense
———
Insider Trading Volume
$17.83$15.97$14.11$12.24$10.38● Close Price0.00M5.00M10.00M15.00M20.00MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Fairmount Funds Management LLCdirector, 10 percent owner:May 11 '26Buy17.001,176,47019,999,9905,090,928May 13 12:00 AM
Mahoney Stephen F.President and CEOMar 03 '26Option Exercise0.0036,714055,071Mar 04 12:00 AM
Beetham Thomas W.Chief Operating OfficerMar 03 '26Option Exercise0.0018,818028,227Mar 04 12:00 AM
Harmon SethChief Financial OfficerMar 03 '26Option Exercise0.0012,534018,801Mar 04 12:00 AM
Tousignant JenniferChief Legal OfficerMar 03 '26Option Exercise0.0010,338015,510Mar 04 12:00 AM
Tousignant JenniferChief Legal OfficerDec 31 '25Sale31.162,27270,7960Jan 02 12:00 AM
Fairmount Funds Management LLCdirector, 10 percent owner:Oct 23 '25Buy22.00454,5459,999,9903,914,458Oct 27 12:00 AM
Fairmount Funds Management LLCdirector, 10 percent owner:Jun 10 '25Option Exercise12.3125,000307,7503,459,913Jun 11 12:00 AM
Fairmount Funds Management LLCdirector, 10 percent owner:Jun 09 '25Option Exercise7.803,20024,9603,447,413Jun 11 12:00 AM
Beetham Thomas W.Chief Operating OfficerSep 27 '24Buy23.415,000117,0506,000Sep 30 12:00 AM
Mahoney Stephen F.President and CEOSep 27 '24Buy23.3321,400499,26221,400Sep 30 12:00 AM
Fairmount Funds Management LLCdirector, 10 percent owner:Sep 13 '24Buy18.751,600,00030,000,0003,445,813Sep 17 12:00 AM
Fairmount Funds Management LLCdirector, 10 percent owner, other: See RemarksJan 22 '24Buy21.00476,1909,999,9901,839,954Jan 24 12:00 AM
Meisner LaraChief Legal OfficerJun 16 '23Option Exercise23.03551,26737,453Jun 20 12:00 AM
Meisner LaraChief Legal OfficerJun 16 '23Sale28.352776529,971Jun 20 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR